
Stimulating insulin secretion from the pancreas when glucose levels are elevated
Inhibiting glucagon release, which prevents excess glucose production by the liver
Slowing gastric emptying, leading to slower digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists support blood sugar control by increasing insulin release and decreasing glucose production in the liver. These drugs are often prescribed when oral medications like metformin are ineffective in managing blood sugar. Some GLP-1 agonists also help reduce the risk of heart-related issues in people with type 2 diabetes and cardiovascular disease.
In those without diabetes, GLP-1 medications such as Wegovy and Saxenda are approved for weight management. By promoting satiety and reducing hunger, these treatments help individuals consume fewer calories without feeling deprived. Studies have shown that combining GLP-1 therapy with lifestyle changes leads to meaningful and sustainable weight loss.
GLP-1 receptor agonists regulate blood glucose levels by stimulating insulin production and suppressing glucagon release after meals. This helps minimize post-meal blood sugar spikes and provides better glycemic control. Since GLP-1 response is glucose-dependent, there is a reduced risk of hypoglycemia compared to traditional diabetes medications, making it a safer choice for many patients.
GLP-1 therapy is particularly effective in supporting long-term weight loss. By slowing the emptying of the stomach and promoting feelings of fullness, these medications reduce appetite, which helps patients control their calorie intake. Studies have shown that medications like liraglutide, semaglutide, and tirzepatide help individuals achieve and maintain significant weight loss when paired with proper diet and exercise.



These drugs enhance insulin secretion and appetite control by stimulating both GLP-1 and GIP receptors, offering better management of blood sugar and hunger. The dual-action approach makes them highly effective for weight management and metabolic disease treatment.
GLP-1/glucagon co-agonists target both receptors to boost weight loss, improve energy metabolism, and preserve lean muscle mass.

